


Amendment of the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. (Currently Amended) A process for extending the lifespan of a mammal metazoan or a mammalian cell metazoan-cells beyond a generic expected lifespan for said mammal or mammalian cell comprising administering to said mammal metazoan-or mammalian cell metazoan-cells a therapeutically effective amount of a composition comprising a C₆₀ C(sub)60 compound or a combination of such C₆₀ compounds, said C₆₀ compounds being represented by the following structure:



wherein C is directly bonded to two adjacent carbons of C(sub)60 and R is independently selected from the group consisting of e,e,e C₆₀(C(COOH)₂)₂(CHCOOH), e,e,e C₆₀(CHCOOH)₃, C₆₀(C(COOH)₂)_n, pharmaceutically acceptable salts of any of the foregoing, pharmaceutically acceptable esters of any of the foregoing, and pharmaceutically acceptable amides of any of the foregoing, wherein the C adjacent the C₆₀ moiety in each of the foregoing formulae is directly bonded to two adjacent carbons of the C₆₀ moiety, wherein n =1, 2, or 3, and wherein said mammal or mammalian cell is not selected for a disability, thereby extending the lifespan of said

mammal or said mammalian cell beyond the generic expected lifespan for said mammal or said mammalian cell by up to about 32%.

2. (Cancelled)
3. (Currently Amended) The process of Claim 1 wherein said at least one said C₆₀ compound is administered in a composition further comprising said C_{(sub)60} compound, its pharmaceutically acceptable salts and pharmaceutically accepted esters, and a pharmaceutically acceptable carrier, present in said composition in a therapeutically effective amount.
4. (Currently Amended) The process of Claim 1 where n is 3 ~~is 4~~.
5. (Currently Amended) The process of Claim 4 wherein said C₆₀ C_{(sub)60} compound is e,e,e C₆₀(C(COOH)₂)₃ C_{(sub)3} tris malonic acid ~~C₆₀~~.
6. (Currently Amended) The process of Claim 1 wherein said C₆₀ C_{(sub)60} compound is administered intravenously, intramuscularly, subcutaneously or orally.
7. (Currently Amended) The process of Claim 6 wherein said C₆₀ C_{(sub)60} compound is administered intravenously, intramuscularly or subcutaneously in an amount of at least 0.1 mg/kg.
8. (Currently Amended) The process of Claim 7 wherein said C₆₀ C_{(sub)60} compound is administered intravenously, intramuscularly or subcutaneously in an amount of about 3 mg/kg.
9. (Currently Amended) The process of Claim 6 wherein said C₆₀ C_{(sub)60} compound is administered orally in an amount of at least 0.1 mg/kg.

10. (Currently Amended) The process of Claim 6 wherein said C₆₀ ~~C_(sub)60~~ compound is administered orally in an amount of about 15 mg/kg.

11. (Currently Amended) The process of Claim 7 wherein said C₆₀ ~~C_(sub)60~~ compound is administered daily.

12. (Currently Amended) The process of Claim 9 wherein said C₆₀ ~~C_(sub)60~~ compound is administered daily.

13.-14. (Cancelled)

15. (Currently Amended) The process of Claim 1 wherein said mammal ~~metazoan~~ is a human.

16.-69. (Cancelled)

70. (New) The process as set forth in Claim 1 wherein an expected lifespan of the mammal or mammalian cell prior to treatment is the generic expected lifespan for said mammal or mammalian cell.